PAHC vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 01, 2026

PAHC

61.0
AI Score
VS
PAHC Wins

PCRX

55.9
AI Score

Investment Advisor Scores

PAHC

61score
Recommendation
BUY

PCRX

56score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PAHC PCRX Winner
Revenue 1.12B 369.77M PAHC
Net Income 78.01M 7.57M PAHC
Net Margin 7.0% 2.0% PAHC
Operating Income 146.24M 11.17M PAHC
ROE 21.6% 1.1% PAHC
ROA 5.4% 0.6% PAHC
Total Assets 1.45B 1.24B PAHC
Cash 54.93M 205.88M PCRX
Debt/Equity 1.71 0.54 PCRX
Current Ratio 3.17 5.04 PCRX

Relative Price Performance (Last 90 Days)

PAHC 1M: -7.9% · 3M: +7.8% PCRX 1M: -4.8% · 3M: -1.1%

Current Technical Phase

PAHC

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 58

RSI (14): 58.2 · Price: $36.78

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.6 · Price: $25.31

Fundamentals Snapshot

Metric PAHC PCRX
Market Cap — —
Forward P/E 10.7 7.3
Trailing P/E 14.7 69.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.3% 0.8%
Operating Margin 0.1% 0.1%
EPS 2.43 0.36
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, PAHC is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.